The CSIR — Central Drug Research Institute (CDRI) Lucknow, has received the nod for finishing up clinical trial of antiviral drug Umifenovir for treating coronavirus sufferers, in accordance to an announcement. The Phase III clinical trials shall be carried out at King George’s Medical University (KGMU), Dr. Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and ERA’s Lucknow Medical College & Hospital, Lucknow, it added.
The drug has a very good security profile and acts by stopping entry of viruses into human cells and in addition by priming the immune system, it added.
Umifenovir is principally used for therapy of influenza and is out there in China and Russia, and has just lately come into prominence due to its potential use for COVID-19 sufferers.
To consider its efficacy in Indian sufferers, CSIR-CDRI has taken up the clinical trial.
Further, it has developed the method know-how for Umifenovir in file time and licensed the economical course of know-how for manufacturing and advertising the drug to M/s. Medizest Pharmaceuticals Private Ltd. Goa, which has already obtained a take a look at license from DCGI, it added.
Prof. Tapas Kundu, Director CSIR-CDRI, stated all of the uncooked supplies for the drug are indigenously accessible and if the clinical trial is profitable, Umifenovir is usually a secure, efficacious, reasonably priced drug in opposition to COVID-19. He added that the drug has the potential for prophylactic use.
Dr Shekhar Mande, Council for Scientific and Industrial Research (CSIR), highlighted that this clinical trial is an integral half of the CSIR technique of repurposing medication for COVID-19.
“The clinical trial application was processed on high priority as per the DCGIs initiative against COVID-19. The next steps of the trial are being fast tracked to enable the availability of the drug to Indian patients as soon as possible,” the assertion added.
CSIR labs have been making an attempt to repurpose totally different medication for treating coronavirus sufferers. For the final three months, the Drug Controller General of India has allowed the use of Favipiravir drug, developed inside the nation by a CSIR laboratory, for clinical trials to deal with coronavirus sufferers.
In one other case, the Council for Scientific and Industrial Research (CSIR), has tied up with Cadila Pharmaceuticals Ltd to consider Mycobacterium W (Mw) for sooner restoration of hospitalised COVID-19 contaminated sufferers.